• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=32229503; PubMed=34732238).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
  

PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032
Meel M.H., Sewing A.C.P., Waranecki P., Metselaar D.S., Wedekind L.E., Koster J., van Vuurden D.G., Kaspers G.J.L., Hulleman E.
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Exp. Cell Res. 360:397-403(2017)

Patent=US20200384022
Suva M.L., Bernstein B.E., Regev A., Filbin M.G., Tirosh I., Hovestadt V.
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas.
Patent number US20200384022, 10-Dec-2020

PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507
Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H., Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S., Yan H.
Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib.
Mol. Cancer Res. 18:968-980(2020)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)